Drug class in one race
CDK4 and CDK6 drugs for HR+/HER2- Metastatic Breast Cancer
6 tracked CDK4 and CDK6 drugs in the HR+/HER2- Metastatic Breast Cancer race. The class explanation lives on the CDK4 and CDK6 page; the full indication pipeline across every mechanism is on the HR+/HER2- Metastatic Breast Cancer page.
3 approved / phase 42 Phase 31 Phase 1/2
Head-to-head evidence: Abemaciclib vs BPI-1178 · Abemaciclib vs BPI-16350 · Abemaciclib vs Dalpiciclib · Abemaciclib vs Palbociclib · Abemaciclib vs Ribociclib · BPI-1178 vs BPI-16350